Globus Medical Surges On Preliminary Q4 And FY25 Sales Results; Issues FY26 Guidance

Globus Medical reported preliminary unaudited Q4 sales of approximately $823.2 million, up 25.2% from $657.3 million a year ago, and FY2025 sales of roughly $2.936 billion, up 16.5% from $2.519 billion. Excluding Nevro acquisition contribution, base business Q4 revenue was $723.3 million, up 10.0%, and management said the April acquisition of Nevro (~$250 million) was accretive in 2025. For 2026 the company guided revenue of $3.18–3.22 billion and non-GAAP diluted EPS of $4.30–$4.40; the update drove an overnight stock jump of ~8.25% to $98.10 (prior close $90.54).

Analysis

Market Structure: Globus (GMED) is the clear direct beneficiary — the Nevro deal added roughly $100M in Q4 (823.2M total vs 723.3M base) and lifts 2025 revenue to $2.936B. Competitors in spine and neuromodulation (e.g., NuVasive NUVA, Medtronic MDT on specific product lines) face incremental share pressure where Globus scales Nevro tech into its US Spine sales channel. The outsized Q4 print signals stronger procedure demand in US Spine; pricing power likely modestly improved via cross-selling rather than raw price increases. Cross-asset impact is limited: expect a modest tightening in healthcare IG spreads and a short-term rise in GMED implied volatility; FX and commodities negligible.

Risk Assessment: Key tail risks are regulatory/antitrust scrutiny of the acquisition, clinical or reimbursement setbacks for Nevro products, and integration margin erosion leading to goodwill write-downs. Immediate (days) risk: post-announcement IV and momentum retracement; short-term (1–3 quarters): integration execution vs synergies and FY26 guide delivery; long-term (2–4 years): sustainability of organic spine growth (10% ex-Nevro Q4) and cadence of further tuck-ins. Hidden dependency: GMED’s growth now levered to successful commercialization of Nevro devices through its US Spine salesforce, not just raw device install volumes. Catalysts: next quarterly release, 1H26 integration metrics, payer coding decisions within 90–180 days.

Trade Implications: Direct play: establish a 2–3% long position in GMED between $90–98, targeting $120 in 6–12 months (midpoint upside ~22–33%), stop-loss $82. Options: buy 12-month LEAP calls (e.g., Jan 2027) or a 6-month call spread to cap cost; consider selling near-term covered calls if harvesting premium post-pop. Pair trade: long GMED (1.5%) / short NUVA (1.5%) to express share shift in spine, or long GMED vs short a broader hospital-equipment ETF to isolate company upside. Rotate modestly overweight to MedTech vs broader HC by 2–3% given better M&A-led upside.

Contrarian Angles: Consensus may be underweight the one-off nature of Nevro lift — ~100M Q4 implies 3–4% of 2025 revenue not guaranteed as recurring organic growth. The 2026 guide midpoint (~$3.20B) implies ~9% growth vs 16.5% in 2025; the market pop may be overdone if investors expect repeat blended growth >12%. Historical M&A in medtech shows acquisitions can compress margins in years 1–2; watch GMED gross margin and SG&A trajectory over next two quarters for signs of integration cost overruns. If margins deteriorate or reimbursement/clinical signals falter, trim positions at the first sign of deteriorating FCF or a >50bp gross-margin decline.

Key Decisions for Investors

• Establish a 2–3% long position in GMED (buy $90–98 window), target $120 in 6–12 months (≈+22–33%), place a stop-loss at $82 to limit downside to ~10–12%.
• Buy a 12-month LEAP call on GMED (e.g., Jan 2027) as a leveraged play with defined risk; alternatively purchase a 6–9 month call spread to keep cost <50% of notional if IV rises ahead of quarterly releases.
• Initiate a pair trade: long GMED (1.5% portfolio) / short NUVA (1.5%) to capture relative share gains in spine; rebalance or unwind after 3 quarters or if GMED misses integration milestones (see next item).
• Monitor these specific metrics over the next 60–180 days before increasing size: (a) Q1 2026 reported revenue vs guide (variance ±2%), (b) gross margin delta vs prior-year (watch for >50bp deterioration), (c) SG&A integration spend and cash flow — reduce exposure if free cash flow falls >10% vs expectation.